Antisense oligonucleotides (ASOs) designed to lower prion protein (PrP) expression in the brain through RNAse H1-mediated degradation of PrP RNA are in development as prion disease therapeutics. ASOs were previously reported to sequence-independently interact with PrP and inhibit prion accumulation in cell culture, yet in vivo studies using a new generation of ASOs found that only PrP-lowering sequences were effective at extending survival. Cerebrospinal fluid (CSF) PrP has been proposed as a pharmacodynamic biomarker for trials of such ASOs, but is only interpretable if PrP lowering is indeed the relevant mechanism of action in vivo and if measurement of PrP is unconfounded by any PrP-ASO interaction. Here we examine the PrPbinding and antiprion properties of ASOs in vitro and in cell culture. Binding parameters determined by isothermal titration calorimetry were similar across all ASOs tested, indicating that ASOs of various chemistries bind full-length recombinant PrP with low-to mid-nanomolar affinity in a sequence-independent manner. Nuclear magnetic resonance, dynamic light scattering, and visual inspection of ASO-PrP mixtures suggested, however, that this interaction is characterized by the formation of large aggregates, a conclusion further supported by the salt dependence of the affinity measured by isothermal titration calorimetry. Sequence-independent inhibition of prion accumulation in cell culture was observed. The inefficacy of non-PrP-lowering ASOs against prion disease in vivo may be because their apparent activity in vitro is an artifact of aggregation, or because the concentration of ASOs in relevant compartments within the central nervous system (CNS) quickly drops below the effective concentration for sequenceindependent antiprion activity after bolus dosing into CSF. ELISA-based measurements of PrP concentration in human CSF were not impacted by the addition of ASO. These findings support the further development of PrP-lowering ASOs and of CSF PrP as a pharmacodynamic biomarker.
Introduction
Prion disease is a fatal, incurable neurodegenerative disease caused by misfolding of the prion protein (PrP) 1 . Antisense oligonucleotides (ASOs) now in preclinical development for prion disease aim to lower PrP expression in the brain, a therapeutic strategy supported by strong genetic proof of concept 2 . These ASOs are being designed to trigger RNAse H1 cleavage of PrP mRNA, a well-established mechanism of action of ASOs [3] [4] [5] . Early studies of ASOs for prion disease, however, left doubt as to whether their efficacy was mediated by RNAse H or by an aptameric mechanism 6 . PrP interacts with diverse polyanions 7, 8 , and nucleic acids including oligonucleotides with the phosphorothioate (PS) backbone widely used in ASOs 9 have shown sequence-independent antiprion activity 6, 10, 11 . PS ASOs have been reported to bind PrP in vitro with nanomolar affinity 10 in a sequence-independent manner, lower PrP expression in cultured cells with micromolar potency 6, 11 , and even strongly inhibit the accumulation of misfolded PrP in prion-infected cultured cells, with low nanomolar potency 6, 10, 11 . In recent studies, PrP-lowering ASOs delivered by intracerebroventricular bolus injection potently extended survival of prioninfected mice, whereas a non-PrP-lowering control ASO conferred no survival benefit 12 . These findings establish RNA-mediated PrP lowering as the mechanism of action of ASOs against prion disease in vivo. Importantly, this mechanism lends itself to measurement of cerebrospinal fluid (CSF) PrP concentration as a pharmacodynamic biomarker for ASO activity 13, 14 . But the question remains as to why the apparently potent aptameric interactions between ASOs and PrP appear not to contribute to in vivo efficacy. Here, we revisit the interaction between ASOs and PrP in vitro and in cell culture. We replicate previous reports of a sequence-independent interaction but provide evidence that this interaction involves aggregation, and that it requires ASO concentrations that may not be sustained in bolus dosing paradigms. Either or both of these factors may explain the lack of sequence-independent activity in vivo.
Results
We used isothermal titration calorimetry (ITC) to estimate the thermodynamic parameters of interactions between full-length recombinant human prion protein (HuPrP23-230) and eight previously described 2, 6, 12 ASOs (Table 1) as well as heparin, a polyanionic positive control 8 (Figure 1 ). All eight ASOs and heparin showed isotherms consistent with a saturable binding event driven by enthalpy, despite a decrease in entropy ( Figure 1C -E). Calculated affinity (Kd) values were similar, in the low-to mid-nanomolar range ( Figure 1C ) for all tested ASOs including a fully phosphorothioated 20mer used as a previous generation of control ASO 6 , and the mixed phosphorothioate/phosphodiester (PS/PO) backbone 15 ASOs with MOE and/or cEt modifications employed more recently 12 . This suggested that the lack of in vivo efficacy of non-PrP-targeting ASOs in recent studies was not due to chemical differences in PrP affinity between ASO chemistries. In an effort to characterize the binding site of ASOs on PrP, we performed protein-observed 1 H- 15 N transverse relaxation-optimized spectroscopy 16 (TROSY) nuclear magnetic resonance (NMR) on 50 µM 15 N-labeled HuPrP23-230, with or without 50 µM ASO. While the control PrP spectrum appeared as expected, virtually all peaks representing PrP backbone amides disappeared when ASO was added ( Figure 2A ). Inspection of the NMR tubes after the fact revealed presence of an opaque white solid, suggesting PrP had precipitated ( Figure 2B ). Subsequent experiments confirmed the formation of visible aggregates within seconds or minutes of addition of ASO to PrP. To quantify this aggregation, we performed dynamic light scattering (DLS) on ASO, PrP, or mixtures of the two. Mass histograms obtained by DLS showed a ~1 nm hydrodynamic radius for 50 µM ASO alone and ~2 nm for 50 µM PrP alone, but when the two were mixed, both of these peaks vanished, replaced with a single peak with a mean hydrodynamic radius of ≥30 nm. These findings suggested that ASOs can aggregate together with recombinant PrP when the two are mixed in vitro.
Figure 2. Aggregation of ASOs and recombinant PrP observed by NMR, DLS, and the naked eye. A) 2D TROSY NMR spectrum of 15 N-labeled HuPrP23-230 with and without ASO. B) Photograph of PrP/ASO mixture (left) and PrP alone (right) from panel A in the NMR tubes. C) Mass histograms from dynamic light scattering of ASO, PrP, and ASO + PrP.
The foregoing results suggested that the PrP-ASO interaction observed in vitro might arise from aggregation. As dependence upon ionic strength has been observed for other aggregators 17 , and given the net positive charge (+7) of PrP and negative charge of ASOs, we then tested the affinity of the PrP-ASO interaction by ITC at variable salt concentrations. For both ASOs tested ( Figure 3A-B ), higher salt concentration corresponded to a reduced change in enthalpy and a lower binding curve slope, both indicative of weaker affinity. At supraphysiological salt levels, 500 mM, no binding was observed.
Figure 3. ASO-PrP interaction depends upon ionic strength. Isothermal titration calorimetry fitted curves for A) active ASO 1 and B) control ASO 4 versus salt concentration.
Given that the biophysical parameters of ASO-PrP interaction appeared similar across ASOs, we sought to replicate, with ASOs recently tested in vivo 12 , the previous reports of sequenceindependent lowering of misfolded PrP accumulation in cell culture. Chronically RML prioninfected mouse neuroblastoma (ScN2a) cells 18 were exposed to ASOs in a gymnotic system (without transfection or electroporation) and harvested for PrP mRNA quantification by qPCR after 24h, or for PrP quantification with or without proteinase K digestion after 72h. Substantial reduction of PrP mRNA and total PrP were observed only for PrP-lowering ASOs and only at micromolar doses ( Figure 4A -B), consistent with limited productive uptake in ScN2a cells. These effective concentrations are orders of magnitude above the EC50 values observed for RNAse H1-mediated activity of potent ASOs either after transfection, or in cells exhibiting productive free uptake of ASOs 19, 20 . In contrast, both PrP-lowering ASOs and a non-targeting control ASO antagonized PK-resistant PrP Sc , consistent with previous reports, albeit with substantial inhibition only at near-micromolar concentrations ( Figure 4C ). PrP Sc has a longer half-life than PrP C , and its clearance by aptamers such as ASOs is time-dependent 6 , so the higher effective concentration observed here may reflect the shorter treatment period (3 days) compared to that previously used (7 days). Measurement of PrP concentration in cerebrospinal fluid (CSF) has been proposed as a pharmacodynamic biomarker for clinical trials of PrP-lowering ASOs 13 , meaning it will be important to be able to accurately measure CSF PrP in the presence of ASO. We sought to determine whether the addition of ASOs would confound measurement of PrP in CSF. We tested a range of ASO concentrations from 1 ng/mL (the lower limit of quantification for some ASOs in CSF 21 ) to 1 mg/mL (the highest concentration that might be reached immediately after bolus dosing in a human 22 ). We began with CSF containing 0.03% CHAPS, as this helps to minimize pre-analytical variability 13 . Addition of ASO up to 1 mg/mL did not result in any detectable change in CSF PrP concentration measured by ELISA ( Figure 5A ). The same was true for heparin ( Figure 5B ). Even in neat CSF lacking detergent, addition of ASO had no effect on the detected PrP concentration ( Figure 5C ).
Figure 5. Presence of ASO does not affect quantification of PrP in CSF. A)
Active ASO 6 spiked into CSF with 0.03% CHAPS. B) Heparin spiked into CSF with 0.03% CHAPS. C) Active ASO 6 spiked into neat CSF.
Discussion
Phosphorothioate oligonucleotides have been reported to bind PrP in vitro in a sequenceindependent manner with nanomolar affinity and to antagonize misfolded PrP accumulation in cell culture with nanomolar efficacy 6,10,11 , yet in vivo, we have reported that only antisense sequences targeting the PrP RNA are effective at extending survival in prion-infected mice 12 . To reconcile these observations, here we revisited the binding of ASOs and PrP. By ITC using recombinant PrP and by immunoblotting in prion-infected ScN2a cells, we replicate the sequence-independent in vitro binding and cell culture antiprion potency of ASOs, and show that these properties are maintained in ASOs that incorporate mixed PS/PO backbones with MOE and/or cEt sugar modifications.
However, we also find evidence, by NMR, DLS, and observation by the naked eye, that the in vitro interaction between otherwise monomeric ASOs and monomeric PrP involves the formation of large aggregates apparently containing both the ASO and PrP. Compounds that aggregate are often considered "pan-assay interference" (PAINS) nuisance compounds 17, 23, 24 . The inhibitory behavior of such compounds is often dependent upon ionic strength 17 , as we observe here for aptameric interactions between ASOs and PrP. The inherent limitations of DLS preclude us from determining whether this aggregation event occurs at lower concentrations of ASO and PrP, such as the nanomolar concentrations used in previous in vitro binding studies 10 , or in complex mixtures such as cell culture media 6, 10, 11 . Thus, our results urge caution around the interpretation of ASO-PrP binding studies, but do not prove that findings in previous reports were necessarily the result of aggregation.
In a small molecule drug discovery campaign, a compound found to exhibit or trigger aggregation would generally be labeled a false positive hit and removed from consideration. The fact that ASOs do exhibit non-sequence-specific antiprion activity in cell culture argues that the binding event may not be purely an in vitro artifact, but rather, might correspond to some genuine interaction at the surface of cultured cells. Nevertheless, ASOs have over 60 documented interacting proteins 25 , PrP binds many polyanions 7 , and indeed, many other polyanions non-specifically bind a large number of different proteins 26 , so the ASO-PrP interaction may not be at all unique or specific. Moreover, several other compounds now understood to be PAINS, such as curcumin and epigallocatechin gallate 24, 27 , were also shown to reduce misfolded PrP accumulation in cell culture 28, 29 and yet lacked any clear in vivo efficacy against prion infections of the CNS 28, 30, 31 . It is therefore perhaps not surprising that a non-PrPlowering ASO might exhibit a similar profile in vitro and in cell culture, and yet lack activity in vivo.
Alternatively, even if ASO-PrP binding as characterized here does occur in vivo, our characterization of the biophysical parameters of this interaction suggests that pharmacokinetics might also be sufficient to explain why non-PrP-lowering ASOs do not extend survival in prioninfected mice. Following bolus injection into CSF, ASOs are rapidly either absorbed into CNS tissue or cleared into plasma 32 . In clinical trials of the ASO nusinersen for spinal muscular atrophy, drug concentration dropped to only ~3 ng/mL (0.4 nM) in CSF by 7 days post-dose 21 . Thus, in a periodic bolus dosing paradigm, concentrations of ASO in the extracellular space and/or in relevant endosomal/lysosomal compartments for PrP binding might not be maintained above the low-to mid-nanomolar Kd values for PrP binding for more than a few hours or days. In contrast, cytosolic and nuclear concentrations of ASO remain above the effective concentration for RNAse H1-mediated activity for months following bolus dosing 22 .
Importantly, despite the interaction between ASO and PrP and despite the ability of ASOs to trigger recombinant PrP precipitation, we find that the presence of ASO in CSF, even at concentrations well above those likely to be sustained in human dosing, does not interfere with quantification of endogenous PrP by ELISA. Thus, measurement of CSF PrP should be able to report on the PrP-lowering effects of an ASO in the human CNS in clinical trials.
Our data support the further development of ASOs for prion disease on the basis of RNAse H1mediated lowering of PrP RNA as mechanism of action and the measurement of PrP in CSF as a pharmacodynamic biomarker to read out this effect.
Methods

Recombinant protein preparation.
Recombinant full-length human PrP (HuPrP23-230) was expressed in E. coli and purified from inclusion bodies by fractionation, denaturation and refolding on a Ni-NTA column as described 33 . The vector was a generous gift from Byron Caughey's laboratory at NIAID Rocky Mountain Labs.
Test compounds. ASOs were prepared and purified as described 12 . Heparin was purchased as a sodium salt purified from porcine intestinal mucosa (Sigma H3393-50KU). This natural source of heparin is of heterogeneous molecular weight, so it is considered in mass/vol rather than molarity terms throughout this study.
Isothermal titration calorimetry. ITC was performed on a MicroCal Auto-ITC200 instrument (Malvern Panalytical, Inc). HuPrP23-230 and ASOs were prepared in dialysis-matched (and, where applicable, NaCl-matched) buffer containing 20 mM phosphate at pH 7.0. Protein was placed in cell and compound in syringe, and each experiment was paired with a control experiment injecting compound into dialysis buffer. Cell temperature was set to 25°C. Each experiment involved 40 injections at 2 second duration (1 µL total volume), at 120 second spacing, with a 5 second filter period, 10 µcal/s reference power, 750 rpm stirring speed, and high gain feedback mode. Data were processed, background-subtracted and curves fit in "single set of sites" mode in the manufacturer's Origin software to obtain thermodynamic parameters.
Nuclear magnetic resonance. 15 N-labeled recombinant HuPrP23-230 was prepared by growing the E. coli in 15 N-enriched cell growth medium (Cambridge Isotope Laboratories CGM-1000-N) supplemented with Overnight Express Autoinduction Medium (Millipore-Sigma 71300-4). 1 H-15 N TROSY spectra were acquired on a 600 MHz Bruker Avance III spectrometer equipped with a 5 mm QCI cryoprobe. Samples contained 50 μM HuPrP23-230 in 20 mM sodium phosphate pH 7.0 with 90% H2O / 10% D2O.
Dynamic light scattering.
HuPrP23-230 and active ASO 1 hydrodynamic radii (Rh) were measured using a DynaPro Plate Reader II (Wyatt Technology) with five 3 second acquisitions. HuPrP23-230 and ASO were used at 50 μM in 20mM sodium phosphate pH 7.0 buffer, and all measurements were performed in a 384-well format (25 μL sample/well) at 25°C. Regularization analysis was used for curve fitting, and Rayleigh spheres were used as the model to determine the Rh.
Tissue culture. ScN2a cells 18 , a generous gift from Sina Ghaemmaghami, were cultured in DMEM media (Life Technologies 11965) supplied with 10% FBS, 1% glutamax, and 1% pen/strep. For RNA measurements, 20,000 cells were seeded per well in 96 well-plates and indicated ASO concentrations were applied in culture media. For protein measurements, 50,000 cells were seeded per well in 12 well-plate and indicated ASO concentrations were applied in culture media.
qPCR. Cells were lysed in 300 µl of RLT buffer (Qiagen, Valencia, CA) containing 1% (v/v) 2mercaptoethanol (BME, Sigma Aldrich). RNA was isolated with an RNeasy 96 Kit (Qiagen) that included in-column DNA digestion with 50 U of DNAse 1 (Thermo Fisher Scientific 18068015). Prnp mRNA in cells was quantified as previously described 12, 34 . Briefly, qPCR was performed on a StepOne Realtime PCR system (Applied Biosystems), with results normalized first to the housekeeping gene cyclophilin A (Ppia) and then to the level in saline-treated cells. Primers and probes were as follows: Prnp forward primer TCAGTCATCATGGCGAACCTT, reverse primer AGGCCGACATCAGTCCACAT, and probe CTACTGGCTGCTGGCCCTCTTTGTGACX. Ppia forward primer TCGCCGCTTGCTGCA, reverse primer ATCGGCCGTGATGTCGA, and probe CCATGGTCAACCCCACCGTGTTCX.
Immunoblotting & PK digest. Cells were lysed at 72 h with lysis buffer containing 0.5% Triton X-100, 0.5% DOC in PBS and spun at 3,000xG for 5 minutes at 4°C. Supernatants were subjected to BCA (Thermo Fisher Scientific 23227) to determine protein concentration. Part of supernatants were saved as PK-sensitive material for total PrP. For PK-resistant PrP Sc , 25 µg total protein was subjected to PK digestion (P6556) using 1µg/ml PK for 5 minutes. Digestion was stopped by adding 1 µL of 25 mM Pefabloc. 20 µg total protein for each sample was run on 4-12% Bis-Tris gels (Thermo Fisher Scientific NP0322) with MES buffer (Thermo Fisher Scientific NP002), probed with 1:500 6D11 antibody (Biolegend 808001) in 5% milk TBS with 0.1% Tween overnight, detected with IRDye 680RD Goat-anti-Mouse IgG, imaged and quantified using Licor Odyssey.
ELISA. Studies on human samples were approved by the Broad Institute's Office of Research Subjects Protection (ORSP-3587). Experiments used previously reported 13 human CSF samples from normal pressure hydrocephalus patients, provided by the Mind Tissue Bank at Massachusetts General Hospital. CSF was stored at -80°C until use. To minimize PrP loss to plastic, experimental CSF handling was minimized. ASO and/or heparin stocks were prepared in PBS in series at 10x the desired final concentration. These stocks were then spiked into separate aliquots of the same CSF sample, premade either with 0.03% CHAPS ( Figure 5A -B) or with no additive ( Figure 5C ). After gentle mixing, spiked CSF samples incubated at room temperature for one hour prior to being assayed. PrP was quantified using the BetaPrion Human ELISA kit (Analytik-Jena) according to the manufacturer's instructions.
Data analysis.
Data were analyzed in R 3.5.1. Dose-response curves (Figure 4) were fit using the drc package 35 with a four-parameter log logistic curve fit (LL.4). Raw data and source code sufficient to reproduce the figures herein are available online at: https://github.com/ericminikel/aso_in_vitro
